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Abstract
Purpose of review—This review highlights recent advances in our understanding of the 
interactions between genetic polymorphisms in genes that metabolize choline and the dietary 
requirements of choline and how these interactions relate to human health and disease.
Recent findings—The importance of choline as an essential nutrient has been well established 
but our appreciation of the interaction between our underlying genetic architecture and dietary 
choline requirements is only beginning. It has been shown in both human and animal studies that 
choline deficiencies contribute to diseases such as non-alcoholic fatty liver disease and various 
neurodegenerative diseases. An adequate supply of dietary choline is important for optimum 
development, highlighted by the increased maternal requirements during fetal development and in 
breast-fed infants. We discuss recent studies investigating variants in PEMT and MTHFR1 that are 
associated with a variety of birth defects. In addition to genetic interactions, we discuss several 
recent studies that uncover changes in fetal global methylation patterns in response to maternal 
dietary choline intake that result in changes in gene expression in the offspring. In contrast to the 
developmental role of adequate choline, there is now an appreciation of the role choline has in 
cardiovascular disease through the gut microbiota-mediated metabolite trimethylamine N-oxide. 
This pathway highlights some of our understanding of how the microbiome affects nutrient 
processing and bioavailability. Finally, in order to better characterize the genetic architecture 
regulating choline requirements, we discuss recent results focused on identifying polymorphisms 
that regulate choline and its derivative products.
Summary—Here we discuss recent studies that have advanced our understanding of how 
specific alleles in key choline metabolism genes are related to dietary choline requirements and 
human disease.
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Introduction
Many diseases have both genetic and environmental risk factors and there is expanding 
interest in identifying interactions between dietary factors and genetic polymorphisms that 
alter either nutrient requirements or susceptibility to disease. This renewed interest in diet 
has been partially prompted by improved –omic technologies used to identify metabolites 
and genetic variants. The interest in environmental effects, such as diet, on disease has been 
in part driven by the surprisingly low heritability uncovered by current genome-wide 
association studies (GWAS). There is now an appreciation that the identification of how 
food (and other environmental factors) interacts with genetic polymorphisms may be key to 
improving health. Clearly, we are moving beyond a “one-size fits all” mentality and 
ultimately a better understanding of gene by diet interactions may help to refine our current 
dietary recommendations.
Of particular interest is the nutrient choline which is found in nuts, dairy, and meat products, 
and was first classified as an essential nutrient based on its role in the prevention of non-
alcoholic fatty liver disease (NAFLD) [1]. An individual’s response to choline deficient 
diets is varied and perhaps an indication of complex genetic regulation of choline 
requirements [2]. Additionally, the requirements for choline may vary across an individual’s 
lifetime as maternal choline deficiency is associated with certain birth defects [3] which 
need to be balanced with the recent evidence that choline-derived metabolites increase CVD 
risk [4–6].
The liver is a primary site of choline metabolism where several metabolic pathways regulate 
maintenance of cell membranes. For cardiovascular risk, phosphatidylcholine synthesis in 
the liver is also important for the assembly of very low-density lipoprotein (VLDL) particles 
that are responsible for transporting fat and cholesterol from the liver to peripheral organs. 
Thus, one effect of choline deficiency is non-alcohol fatty liver disease (NAFLD) and this 
may be a direct result of reduced levels of hepatic phosphatidylcholine leading to hepatic 
accumulation of fat and cholesterol. Genetic polymorphisms in genes regulating choline 
metabolism have been extensively studied as they have been hypothesized to modify 
requirements for choline. These are outlined in Figure 1 and described in detail below.
Genetic polymorphism, dietary choline, and pregnancy outcomes
Much of the interest in choline as an essential nutrient is due to previous reports of low 
choline being associated with certain birth defects [7–9]. In addition to choline intake, there 
has been substantial interest in either the mother’s genotype or fetal genotype influencing 
fetal choline requirements or metabolism. The premise is that identifying mothers with 
altered choline need or metabolism may reduce negative outcomes.
Certain polymorphisms may be particularly deleterious in the presence of dietary choline 
deficiencies [10, 11]. For example, polymorphisms in the gene methylenetetrahydrofolate 
dehydrogenase 1 (MTHFD1), specifically the A allele of MTHFD1 G1958A, may affect 
homocysteine methylation when folate availability is low [12, 13]. Thus polymorphisms of 
MTHFD1 have been associated with various congenital abnormalities such as neural tube 
defects [14], Down’s Syndrome, cleft lip, cleft palate [15], and congenital heart defects. 
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There is some heterogeneity in these data as studies have inconsistently reported the 
association of specific effect alleles (or underlying polymorphisms), so additional work is 
necessary to clarify the risk variants and their effect size. More recently, meta-analyses have 
identified associations between MTHFD1 polymorphisms, such as the MTHFD1 G1958A 
variant, as being associated with increased risk for birth defects [16], [17], [18]. 
Additionally, two missense mutations, rs7946 and rs897453, in PEMT, an enzyme required 
for de novo production of choline, have been associated with altered homocysteine levels 
and neural tube defects, respectively [19, 20].
However, data directly linking neural tube defects (NTDs) and maternal choline levels and 
specific polymorphisms are inconsistent. Recently, Mills et al conducted a study to 
investigate the link between NTDs and maternal choline levels and associated SNPs. They 
measured choline and betaine levels and looked at SNPs in PEMT in women with a current 
NTD-affected pregnancy, women with a previous NTD-affected pregnancy currently 
pregnant and unaffected, and unaffected control women. They reported that the levels of 
choline and betaine did not differ in women who had a current NTD-affected pregnancy. 
Cases were significantly more likely to have the G allele of PEMT rs7946 (V175M, +5465 
G.A) [15]. It is quite possible that these polymorphisms affect fetal or maternal choline 
requirements but it was not possible to measure umbilical cord metabolite levels in this 
particular study. Another group recently compared maternal plasma levels of choline, 
betaine, dimethylglycine, and trimethylamine N-oxide (TMAO) in pregnant women at 16 
weeks of gestation, at delivery, and in umbilical cord plasma [21]. Mean maternal plasma 
free choline, dimethylglycine, and TMAO concentrations increased during pregnancy by 
49%, 17%, and 13%, respectively, while betaine concentrations decreased by 21%. 
Curiously, cord plasma concentrations of free choline and betaine were 3.2 and 2.0 times 
higher than maternal plasma values at delivery, indicating perhaps an altered requirement for 
these metabolites by the fetus. The authors did not find an association between maternal 
diet, as assessed by a food frequency questionnaire, and cord plasma concentrations of 
choline nor did they find any associations between fetal genotype of 10 candidate SNPs and 
cord plasma concentrations of choline. Improving our understanding of how maternal 
dietary requirements and genetics interact to affect fetal health has important public health 
implications.
Epigenetic effects
An area of intense interest is the effect of maternal diet on offspring due to altered 
epigenetic marks that control gene expression [22]. Choline is particularly interesting as it is 
a methyl donor and thus differences in choline status could affect global DNA methylation. 
Studies in rodents have found that the gestational availability of choline has a large impact 
on DNA methylation and researchers are focusing on understanding how these specific 
changes in methylation may affect disease risk. A study using a toxic milk (tx-j) mouse 
model of Wilson’s Disease on a C3H/HeJ background found that maternal choline 
supplementation altered transcript levels of methionine and lipid metabolism genes. In this 
study, maternal choline supplementation increased global DNA methylation measured in 
fetal livers, indicating the importance of dietary choline during fetal development [23]. 
Additional studies have argued that the availability of methyl donors is tightly regulated, and 
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that high levels of methylation are not universally protective as increased DNA methylation 
may be linked to behavioral disorders [24–26].
Understanding the effects of choline and 1-carbon metabolites on the human epigenome is 
an area of active investigation. Interestingly, although not surprisingly, the effects of choline 
deficiency have been identified as population specific, likely due to differences in gene 
allele frequency in certain populations as well as dietary differences among populations. In a 
recent study focused on women in rural Gambia, researchers showed that seasonal variations 
in methyl-donor nutrient intake in mothers as early as conception influenced maternal 
plasma concentrations of several key methyl-donor pathway substrates, including choline, 
betaine, methionine, and homocysteine, which in turn were shown to influence the 
methylation status of fetal alleles [27].
Genetic polymorphism, dietary choline, and metabolic disease
Initial interest in choline metabolites and CVD arose via the association between 
homocysteine levels and CVD, but this association is now considered inconclusive [28]. To 
better understand these data, recent research has focused on specific polymorphisms that 
alter homocysteine levels such as those in MTHFR, the enzyme that converts 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is a substrate required for 
conversion of homocysteine to methionine. The SNP rs1801133 has been linked to elevated 
plasma homocysteine levels and increased risk of CAD [29]; however, the mechanisms by 
which elevated homocysteine levels promote CAD are still not well understood and other 
studies have failed to replicate this result [30]. Studies in different ethnicities have identified 
a similar association between A1298C and CVD in two independent Indian populations [31, 
32]. A meta-analysis of 6912 individuals confirmed that the C677T polymorphism is also 
associated with premature CAD [33]. It is not clear from these studies if different choline 
intake (dietary substrate) is the source of these disparate results. It is important to note that 
some of the heterogeneity in the literature may in fact be due to dramatic differences in 
folate levels supplied in the diet. In 1997 folate supplementation was mandated and thus it is 
possible that certain results are discordant due to this difference in substrate availability for 
these enzymatic reactions.
More importantly, a recent randomized clinical trial to evaluate the efficacy of folic acid 
therapy in the prevention of strokes grouped participants based on MTHFR C677T genotype. 
This study found that folic acid therapy significantly reduced stroke risk among participants 
with the CC or CT genotypes, but not among those with the TT genotype [34] and these 
results may extend to renal disease [35]. The association of MTHFR is complicated as SNPs, 
including rs13306561, rs1801133, and rs17367504, in the gene have been associated with 
increases in diastolic blood pressure, but these associations have not replicated across 
studies [36, 37]. There is a possibility that some of the effects of these polymorphisms 
mediate expression of MTHFR from the recent identification of a polymorphism at the locus 
that affects its expression, also known as a cis-eQTL. This variant has also been associated 
with CVD related traits [38].
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There is evidence that genetic variations in the PEMT gene also affect choline metabolism. 
Polymorphisms such as the variant tagged by the C allele of rs12325817 in PEMT were 
found to be associated with development of organ dysfunction in individuals fed a choline 
deficient diet [2]. Furthermore, previous results have shown an interesting interaction of 
PEMT and estrogen signaling. For this reason, of particular interest are two potential 
functional variants: an amino acid substitution, Val58Leu (rs897453), in a transmembrane 
domain of PEMT and rs750546 which is found in the ESR1 binding site of PEMT [39]. The 
specific effect of these polymorphisms on CVD risk remains unknown but the importance of 
PEMT in CVD was shown by recent studies in genetically modified mice [40]. For example, 
Pemt−/− mice have reduced circulating homocysteine levels and resistance to atherosclerotic 
lesions, signifying the importance of PEMT in CVD [41]. Pemt−/− mice also exhibit low 
plasma VLDL levels and develop fatty livers in response to a high fat diet, which was 
partially ameliorated when the diets were supplemented with choline as hepatic cholesterol 
levels decreased and liver function improved. These data suggest that genetic variants of 
PEMT alter dietary choline requirements and that choline requirements could vary by an 
individual’s genotype.
The gut microbiome regulates choline levels and contributes to complex 
diseases in humans
For several years, researchers have studied the role of the gut microbiome in complex 
diseases such as cancer, obesity, diabetes, CVD, and NAFLD [42–45]. Direct links have 
been made between these various diseases and the regulation of choline levels, especially in 
situations of dietary choline deficiency [46]. TMAO, a derivative of choline, was identified 
as a predictive biomarker linking the microbiome and CVD risk [47, 48]. TMAO is an 
oxidation product of trimethylamine (TMA) that is found in both humans and mice. TMAO 
is synthesized as a conversion product from TMA, which is derived from the breakdown of 
dietary choline-containing compounds by the gut microbiota.
There are widespread differences in the microbiota composition among humans that could 
affect the metabolism and bioavailability of dietary choline. For example, Romano et al 
identified several isolates, from a collection of 79 sequenced human intestinal samples, 
capable of producing TMA from choline in vitro. They identified nine bacterial strains 
capable of producing TMA from choline in vitro and tested these using gnotobiotic mice to 
show that TMAO accumulates in the serum of animals colonized with TMA-producing 
species. Remarkably, low levels of colonization by TMA-producing bacteria significantly 
reduced choline levels available to the host which was more pronounced as the abundance of 
TMA-producing bacteria increased in the gnotobiotic mice [49]. These important studies 
indicate that the composition of the microbiome affects plasma TMAO and choline 
concentrations. These results are particularly intriguing given studies that have shown that 
egg consumption leads to increased TMAO concentrations in the blood [47]. This result was 
confirmed in a small clinical study that demonstrated that 11–15% of dietary total choline is 
converted into TMAO after consumption of a meal that contained eggs [6].
Normally, TMA is oxidized to TMAO primarily through the action of flavin mono-
oxygenase 3 (FMO3). Studies in mice have shown a direct link between plasma levels of 
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TMAO, Fmo3 expression, and atherosclerosis [5]. More recent studies have identified Fmo3 
as a key metabolic gene that affects lipid and glucose metabolism. Studies in LDLr−/− mice 
treated with antisense Fmo3 oligonucleotides exhibited decreases in hepatic lipids and in 
levels of plasma lipids, ketone bodies, glucose, and insulin, whereas opposite effects were 
observed with transgenic mice overexpressing Fmo3 [50]. Knockdown of Fmo3 in 
cholesterol-fed mice alters biliary lipid secretion, blunts intestinal cholesterol absorption, 
and limits the production of hepatic oxysterols and cholesteryl esters. Furthermore, FMO3 
knockdown stimulates basal and liver X receptor (LXR)-stimulated macrophage RCT, 
thereby improving cholesterol balance [51].
Novel regulatory variants and choline status
Identification of genetic variants affecting choline requirements could be used to refine our 
dietary recommendations in pregnancy and in cardiovascular patients. A targeted genetic 
study of 200 SNPs in ten candidate genes selected for their biochemical importance in 
choline metabolism identified novel associations with liver and muscle function in subjects 
fed a low-choline diet [52]. The authors used a combination of clinical studies in which 
patients were fed a choline deficient diet while under medical supervision and were deemed 
to have organ dysfunction when they developed increased creatine phosphokinase or 
aspartate aminotransferase levels. Genotypes were then compared between patients with 
organ dysfunction and patients that were resistant to choline restriction. Novel SNPs in 
SLC44A1, CHKA, and CHKB were identified as associated with increased choline 
requirements, and there was an indication that some of the SNPs in SLC44A1 may 
differentiate between patients that develop muscle dysfunction or hepatic dysfunction. The 
authors then tested the allele frequency of these SNPs in Mexican Americans, European 
Americans, Asian Americans and Africans (n=100 per population) and several of the SNPs 
associated with choline requirements in the clinical study were dramatically different 
between these small population cohorts. For example rs7873937, a SNP in SLC44A1, was 
present in all populations except Asian Americans. They concluded that these differences in 
allele frequency could alter the choline requirement in a population-specific manner [52]. 
These data are supported by a case report of a patient with postural orthostatic tachycardia 
syndrome. This patient had decreased levels of the choline transporter SLC44A1 and reduced 
plasma choline levels, suggesting an intriguing link between SLC44A1 and plasma choline 
[53]. These data suggest that genetic variants of choline metabolizing enzymes can alter 
dietary choline requirements and that choline requirements could vary by an individual’s 
genotype.
The identification of SNPs in key genes regulating choline metabolism as associated with 
human diseases across multiple general populations and among small isolated populations 
indicates the importance of this pathway in regulating multiple complex processes 
contributing to human health. Dietary choline intake varies geographically and different 
populations exhibit different allele frequencies in key choline metabolism genes. For this 
reason, a recently published study sought to identify whether key SNPs that increase 
dependence on dietary choline would be under selective pressure specifically in a 
geographic location with a prevalent choline-poor diet [10]. They assessed CHDH rs12676, 
MTHFD1 rs2236225, and PEMT rs12325817 for negative selective pressure in The Gambia, 
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West Africa, known for its choline-deficient diet, versus two other populations with choline-
rich diets, including a genetically similar population in Maasai in East Africa and a 
genetically dissimilar population the United States. The authors used two different genetic 
models to demonstrate minor allele frequencies of polymorphisms associated with increased 
choline requirements between the Gambian and the other populations. Although difficult to 
definitively test in this particular study, the authors hypothesize that the dramatic difference 
in allele frequency is actually driven by historical dietary differences between these 
populations. These data do present the intriguing question of whether our genetically 
programmed needs for specific nutrients may in fact be partially determined by ethnicity 
and/or selective pressures due to historical diets of our ancestors.
In addition to genes that may affect the metabolism of choline, recent studies have been 
focused on determining the genetics underlying the association of TMAO to CVD since this 
metabolite is a by-product of microbial metabolism of choline. Based on the highly variable 
plasma TMAO levels observed in human studies, it is reasonable to hypothesize that TMAO 
levels are affected by the intrinsic genetic factors of the host. However, with the exception 
of FMO3, deficiency of which leads to elevated TMA and decreased TMAO levels [5], the 
genes that control plasma TMAO levels are not known. A comparative GWAS approach 
using a large mouse genetic reference population and ~2000 subjects was used to identify 
candidate genes [4]. These studies identified a genome-wide significant locus on 
chromosome 3 associated with plasma TMAO concentrations in mice on a chow diet (p= 
2.37x10−6). This locus also exhibited highly significant evidence (p=1.07x10−20) for cis-
regulation of solute carrier family 30 member 7 (Slc30a7) expression in the liver. The co-
localization of loci for plasma TMAO and Slc30a7 mRNA levels suggest that this zinc 
transporter represents a positional candidate gene responsible for the association signal at 
this locus. By comparison, no locus exceeding the genome-wide significance threshold was 
observed in the human GWAS, including the orthologous region on human chromosome 
1p21.2 harboring SLC30A7 or at the FMO3 locus, which indicates the complex genetic 
regulation of TMAO concentrations. Supporting these findings, a GWAS in the Framingham 
Heart Study (FHS) also failed to detect significant associations for plasma TMAO 
concentrations, although several suggestively associated loci were also identified [54]. 
Further GWAS investigations that account for differences in choline or l-carnitine intake 
may better identify genes regulating plasma levels of TMAO.
Conclusion
We are just beginning to understand the complex interactions between diet and genetic 
polymorphisms. Here we discuss choline as it has been shown to be a clinically important 
nutrient that has been associated with diseases of deficiency, in the case of birth defects, 
while excessively elevated choline levels are associated with CVD risk. Polymorphisms in 
several candidate genes demonstrate that genetic perturbations can affect the metabolism of 
choline and presumptively an individual’s dietary requirement for choline. Studies with rural 
African populations have demonstrated altered methylation status and indicated unique 
selective pressures on genes regulating choline metabolism. Studies in mice and humans 
with CVD indicate that gut microbial metabolism, and perhaps genetic polymorphisms of 
the host, influence the conversion of dietary choline into the pro-atherogenic metabolite 
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TMAO. Clearly additional work to identify the underlying genetic variants and how they 
relate to dietary choline requirements across a lifetime are necessary before altering our 
current recommendations.
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Key Points
• Insufficient intake of dietary choline in pregnant women is associated with 
developmental disorders.
• Certain populations are more susceptible to choline-related diseases due to the 
low availability of dietary choline and the presence of polymorphism that alter 
dietary choline requirements.
• Choline is a methyl donor and choline deficiency has been shown to alter global 
methylation patterns.
• Understanding how common polymorphisms influence dietary choline 
requirements may allow for a more personalized approach to dietary 
recommendations.
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Figure 1. Genes involved in Choline Metabolism: We discuss genetic variants in several genes 
known to affect choline metabolism
Known genes regulating choline metabolism and dietary choline requirements. PEMT 
catalyzes the synthesis of phosphatidylcholine from phosphatidylethanolamine, a precursor 
of endogenously derived choline. The transporter SLC44A1 can transport choline into the 
mitochondria for further processing. In the gut, choline is the precursor of trimethylamine 
which is absorbed and transported to the liver for oxidation by FMO3 
(flavinmonooxygenase 3) to TMAO. Choline is the precursor of betaine, which serves as a 
source of methyl groups for homocysteine remethylation to dimethylglycine and methionine. 
Alternatively, homocysteine can be remethylated with methyl groups from 5-
methyltetrahydrofolate, which is derived from 5,10-methylenetetrahydrofolate. MTHFD1 
(methylenetetrahydrofolate dehydrogenase 1), an enzyme that catalyzes the production of 
5,10-methylenetetrahydrofolate from 5,10-methenyltetrahydrofolate.
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